Health Care Equipment

ReShape Lifesciences

ReShape Lifesciences Inc Restores Compliance With NASDAQ's Minimum Stockholders' Equity Requirements

ReShape Lifesciences Announces Layoffs and Updates Merger and Asset Sale Agreements

ReShape Lifesciences Raises $2.6 Million Through Stock Offering

ReShape Lifesciences and Recon Supply Sign Exclusive Distribution Agreement for Medical Products

ReShape Lifesciences Inc. public offering

ReShape Lifesciences Receives EU MDR Certification

ReShape Lifesciences Announces Merger with Vyome Therapeutics

ReShape Lifesciences Reports Q1 2025 Financials and Executes Reverse Stock Split

ReShape Lifesciences released FY2025 Q1 earnings on May 20 (EST), actual revenue USD 1.113M, actual EPS USD 18.9782

ReShape Lifesciences Inc Submits Up to $50 Million Shelf Offering Application

ReShape Presents Clinical Data for Diabetes Neuromodulation Device

ReShape Lifesciences Gastric Balloon System Patent Approved by US

ReShape Lifesciences® Receives Patent for Diabetes Treatment Technology

Reshape Signs Exclusive Distribution Agreement in the U.S. Neuromuscular Rehabilitation Market

ReShape Lifesciences released FY2024 earnings on April 4 (EST), actual revenue USD 8.006 M (forecast USD 9.994 M), actual EPS USD -345.7304 (forecast USD -652.4992)

ReShape Lifesciences released FY2024 Q4 earnings on April 4 (EST), actual revenue USD 1.805 M (forecast USD 3.173 M), actual EPS USD -61.7093 (forecast USD -101.4998)

ReShape Lifesciences FY2024 Q4 Earnings Release on April 10 During-Market EST, Forecasted Revenue 3.173 M USD, EPS -4.06 USD

ReShape Lifesciences Receives Notification of Allowance in the United States

ReShape Lifesciences Obtains US Patent for Vagus Nerve Modulation Technology to Treat Type 2 Diabetes

ReShape Lifesciences Announces $6 Million Public Offering to Support Weight Loss and Metabolic Health Solutions

Luminar Tech

Novabay Pharmac

Mint Incorporation

Autozi Internet Tech Global

GD Culture

Impact BioMedical

Tradr 2X Long FLY Daily ETF

Leverage Shares 2X Long CRWV Daily ETF

T-REX 2X Long CRWV Daily Target ETF

Delcath

Electromed

雅培

直觉外科

波士顿科学

史赛克

IDEXX实验室

爱德华生命科学

瑞思迈

德康医疗

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap